Q-omics provides the consensus-scored ENPP7P5 profile across patient tissues and cancer cell-line models. ENPP7P5 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, ENPP7P5 is differentially expressed in 5, with the highest sampling consensus in STAD. Additionally, ENPP7P5 RNA expression shows 14,930 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight DLBC, STAD, and TGCT as cancer lineages where ENPP7P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ENPP7P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ENPP7P5 survival associations across molecular data types. ENPP7P5 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ENPP7P5 RNA expression–survival associations across cancer types. High ENPP7P5 expression shows unfavorable associations in DLBC, LUSC, KIRC, MESO and KICH, but favorable associations in LGG. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for ENPP7P5 RNA expression.
This table summarizes ENPP7P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for ENPP7P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ENPP7P5 shows lower tumor expression in KICH and THCA and higher tumor expression in STAD, READ and CHOL. The STAD box plot shows higher ENPP7P5 RNA expression in tumor versus normal tissue (log2 FC = +0.143, t-test p = .006).
This table shows molecular features associated with ENPP7P5 in patient tissues and cancer cell lines. In patient samples, ENPP7P5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
